Kodiak Sciences’ (KOD) “Neutral” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Kodiak Sciences (NASDAQ:KOD) in a research report released on Monday morning,Benzinga reports. HC Wainwright currently has a $3.00 price objective on the stock. HC Wainwright also issued estimates for Kodiak Sciences’ Q1 2025 earnings at ($0.90) EPS and FY2029 earnings at ($1.51) EPS.

Separately, Jefferies Financial Group raised Kodiak Sciences from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a research report on Monday, December 9th.

Kodiak Sciences Stock Up 4.3 %

KOD stock opened at $2.67 on Monday. The firm has a market cap of $140.51 million, a P/E ratio of -0.73 and a beta of 2.26. Kodiak Sciences has a 52-week low of $2.19 and a 52-week high of $11.60. The company’s 50-day simple moving average is $4.55 and its 200-day simple moving average is $5.43.

Kodiak Sciences (NASDAQ:KOD) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.84) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.06. On average, analysts anticipate that Kodiak Sciences will post -3.45 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of KOD. PNC Financial Services Group Inc. lifted its holdings in shares of Kodiak Sciences by 1,501.5% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,187 shares of the company’s stock valued at $32,000 after purchasing an additional 2,988 shares in the last quarter. US Bancorp DE acquired a new position in Kodiak Sciences in the 4th quarter worth $40,000. Headlands Technologies LLC bought a new position in shares of Kodiak Sciences during the fourth quarter worth about $90,000. Fox Run Management L.L.C. acquired a new stake in Kodiak Sciences during the fourth quarter worth about $118,000. Finally, Jump Financial LLC acquired a new stake in shares of Kodiak Sciences in the 4th quarter worth about $147,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.